NASDAQ:MACKMerrimack Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Merrimack Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.51 +0.17 (+5.09 %) (As of 08/11/2020 04:00 PM ET) Add Compare Share Today's Range$3.35Now: $3.51▼$3.5150-Day Range$3.10MA: $3.33▼$3.5952-Week Range$1.49Now: $3.51▼$7.09Volume46,492 shsAverage Volume35,250 shsMarket Capitalization$46.96 millionP/E RatioN/ADividend YieldN/ABeta2.45 ProfileAnalyst RatingsAdvanced ChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Merrimack Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. The company has a collaboration and license agreement with Ipsen S.A. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Merrimack Pharmaceuticals. Previous Next 2.9 Community Rank Outperform VotesMerrimack Pharmaceuticals has received 400 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMerrimack Pharmaceuticals has received 297 “underperform” votes. (Add your “underperform” vote.)Community SentimentMerrimack Pharmaceuticals has received 57.39% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote “Outperform” if you believe MACK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMerrimack Pharmaceuticals does not currently pay a dividend.Dividend GrowthMerrimack Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Merrimack Pharmaceuticals insiders have bought 51.74% more of their company's stock than they have sold. Specifically, they have bought $551,322.00 in company stock and sold $363,326.00 in company stock.Percentage Held by InsidersOnly 21.60% of the stock of Merrimack Pharmaceuticals is held by insiders.Percentage Held by Institutions48.30% of the stock of Merrimack Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioMerrimack Pharmaceuticals has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.38 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:MACK Previous Symbol CUSIP59032810 CIK1274792 Webwww.merrimackpharma.com Phone617-441-1000Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book2.70Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-17,330,000.00 Net MarginsN/A Return on Equity-12.40% Return on Assets-10.38%Miscellaneous Employees27 Outstanding Shares13,380,000Market Cap$46.96 million Next Earnings Date11/10/2020 (Estimated) OptionableOptionable $3.51 +0.17 (+5.09 %) (As of 08/11/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MACK News and Ratings via Email Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter. Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions How has Merrimack Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Merrimack Pharmaceuticals' stock was trading at $2.76 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MACK stock has increased by 27.2% and is now trading at $3.51. View which stocks have been most impacted by Coronavirus. When is Merrimack Pharmaceuticals' next earnings date? Merrimack Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Merrimack Pharmaceuticals. How were Merrimack Pharmaceuticals' earnings last quarter? Merrimack Pharmaceuticals Inc (NASDAQ:MACK) announced its quarterly earnings data on Friday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.92) by $0.14. View Merrimack Pharmaceuticals' earnings history. How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals? Merrimack Pharmaceuticals declared a -- dividend on Wednesday, December 4th. Stockholders of record on Monday, December 16th will be given a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date of this dividend is Friday, December 13th. View Merrimack Pharmaceuticals' dividend history. When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work? Merrimack Pharmaceuticals shares reverse split on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split. Has Merrimack Pharmaceuticals been receiving favorable news coverage? Headlines about MACK stock have trended somewhat positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Merrimack Pharmaceuticals. Are investors shorting Merrimack Pharmaceuticals? Merrimack Pharmaceuticals saw a increase in short interest in the month of July. As of July 31st, there was short interest totaling 530,400 shares, an increase of 8.4% from the July 15th total of 489,200 shares. Based on an average trading volume of 25,900 shares, the short-interest ratio is presently 20.5 days. Approximately 4.1% of the shares of the stock are short sold. View Merrimack Pharmaceuticals' Short Interest. Who are some of Merrimack Pharmaceuticals' key competitors? Some companies that are related to Merrimack Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Merrimack Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL) and Amicus Therapeutics (FOLD). Who are Merrimack Pharmaceuticals' key executives? Merrimack Pharmaceuticals' management team includes the following people: Dr. Richard Peters, Pres, CEO & Director (Age 56)Ms. Jean M. Franchi, CFO & Treasurer (Age 53)Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)Dr. Sergio L. Santillana, Chief Medical Officer (Age 56) What is Merrimack Pharmaceuticals' stock symbol? Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK." How do I buy shares of Merrimack Pharmaceuticals? Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Merrimack Pharmaceuticals' stock price today? One share of MACK stock can currently be purchased for approximately $3.51. How big of a company is Merrimack Pharmaceuticals? Merrimack Pharmaceuticals has a market capitalization of $46.96 million. Merrimack Pharmaceuticals employs 27 workers across the globe. What is Merrimack Pharmaceuticals' official website? The official website for Merrimack Pharmaceuticals is www.merrimackpharma.com. How can I contact Merrimack Pharmaceuticals? Merrimack Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected] This page was last updated on 8/12/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
